The role of glutamatergic pathways in schizophrenia: From animal models to human imaging studies

Clinical Neuropsychiatry

Volumn 4, Issue 5-6, 2007, Pages 199-207

  Brambilla, Paolo ^a,b,c,d,h   Riva, Marco A ^e   Melcangi, Roberto C ^e   Diwadkar, Vaibhav A ^f,g  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SCIENTIFIC INSTITUTE   (Italy)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Glutamate; Glutamatergic neurotransmission; Pathophysiology of schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DEXTRO AMINO ACID OXIDASE; DOPAMINE; DYSBINDIN; GLUTAMIC ACID; KAINIC ACID; KETAMINE; MYELIN; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; RGS4 PROTEIN;

BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN SIZE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUTAMATERGIC TRANSMISSION; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; LEARNING; MEMORY; MENTAL TASK; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; SYMPTOM;

EID: 46949094638     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Achim AM, Bertrand MC, Sutton H, Montoya A, Czechowska Y, Malla AK, et al. (2007). Selective abnormal modulation of hippocampal activity during memory formation in first-episode psychosis. Arch Gen Psychiatry 64, 9, 999-1014.
2. Adler CM, Goldberg TE, Malhotra AK, Pickar D, Breier A (1998). Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol Psychiatry 43, 11, 811-816.
3. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52, 4, 258-66.
4. Andreone N, M Tansella, R Cerini, A Versace, G Rambaldelli, C Perlini, N Dusi, L Pelizza, M Balestrieri, C Barbui, M Nosè, A Gasparini, Brambilla P (2007). Cotrical white matter microstructure in schizophrenia. Diffusion imaging study. British Journal of Psychiatry 191, 113-119.
5. Arai AC, Kessler M (2007). Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 8, 583-602.
6. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC (2001). Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25, 157-164.
7. Bartzokis G, Altshuler L (2005). Reduced intracortical myelination in schizophrenia. Am J Psychiatry 162, 1229-1230.
8. Baslow MH (1997). A review of phylogenetic and metabolic relationships between the acylamino acids, N-acetyl-L-aspartic acid and N-acetyl-L-histidine, in the vertebrate nervous system. J Neurochem 68, 4, 1335-44.
9. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, et al. (1996). Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 153, 12, 1554-1563.
10. Best PJ, White AM, Minai A (2001). Spatial processing in the brain: the activity of hippocampal place cells. Annu Rev Neurosci 24, 459-486.
11. Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 3, 2, 8049, 1157-8.
12. Bliss TV, Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 6407, 31-39.
13. 1H MRS Brain Measures and acute lorazepam administration in healthy human subjects. Neuropsychopharmacology 26, 546-551.
14. Brambilla P, J Perez, G Schettini, F Barale, JC Soares (2003). GABAergic dysfunction in mood disorders. Mol Psychiatry 8, 721-738.
15. 1H MRS study of dorsolateral prefrontal cortex in healthy individuals before and after lithium administration. Neuropsychopharmacology 29, 1918-1924.
16. Brambilla P, M. Tansella (2007). The role of white matter for the pathophysiology of schizophrenia. International Review of Psychiatry 19, 459-68.
17. Breese CR, Freedman R, Leonard SS (1995). Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 674, 1, 82-90.
18. Buchel C, Coull JT, Friston KJ (1999). The predictive value of changes in effective connectivity for human learning. Science 283, 1538-1541.
19. Chambers JS, Perrone-Bizzozero NI (2004). Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem Res 29, 2293-2302.
20. Chambers L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K (2007). Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 62, 12, 1396-404.
21. Chen J, Lipska BK, Weinberger DR (2006). Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 59, 1180-1188.
22. Compte A, Brunel N, Goldman-Rakic PS, Wang XJ (2000). Synaptic mechanisms and network dynamics underlying spatial working memory in a cortical network model. Cereb Cortex 10, 9, 910-923.
23. Corfas G, Roy K, Buxbaum JD (2004). Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7, 575-580.
24. Coyle JT (2004). The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem Pharmacol 68, 8, 1507-1514.
25. Davis KL, Stewart DG, Friedman JI, et al (2003). White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60, 443-456.
26. Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW (1998). Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry 43, 7, 483-488.
27. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V (2006). Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21, 531-540.
28. Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, Lieberman JA, Snouwaert JN, Koller BH (2004). Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153, 507-519.
29. Dwork AJ, Mancevski B, Rosoklija G (2007). White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol 10, 513-36.
30. Edelman GM (1993). Neural Darwinism: selection and reentrant signaling in higher brain function. Neuron 10, 2, 115-125.
31. Flynn SW, Lang DJ, Mackay AL, et al (2003). Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 8, 811-820.
32. Fries P, Fernandez G, Jensen O (2003). When neurons form memories. Trends Neurosci 26, 3, 123-124.
33. Friston K (2003). Learning and inference in the brain. Neural Netw 16, 9, 1325-1352.
34. Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L, Holmans P, MacGregor S, Zammit S, Wilkinson J, Williams H, Nikolov I, Williams N, Ivanov D, Davis KL, Haroutunian V, Buxbaum JD, Craddock N, Kirov G, Owen MJ, O'Donovan MC (2006). Convergent evidence that oligodendrocyte lineahe transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. PNAS 103, 12469-12474.
35. Ghose S, Weickert CS, Colvin SM, Coyle JT, Herman MM, Hyde TM, Kleinman JE (2004). Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia. Neuropsychopharmacology 29, 1, 117-25.
36. Greene JG, Greenamyre JT (1996). Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 48, 613-34.
37. Greene R (2001). Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11, 5, 569-577.
38. Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z (2005). Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25, 4974-4984.
39. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ, Gallop RJ, Arnold SE (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12, 824-828.
40. Hardy RJ (1998). Molecular defects in the dysmyelinating mutant quaking. J Neurosci Res 51:417-422.
41. Haroutunian V, Davis KL (2007). Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol 10, 499-502.
42. Harrison PJ, Law AJ, Eastwood SL (2003). Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci 1003, 94-101.
43. Harrison PJ (2004). The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 174, 1, 151-162.
44. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10, 40-68.
45. Harrison PJ, Law AJ (2006). Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60, 132-140.
46. Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ, et al. (1998). Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci 1, 4, 318-323.
47. Heresco-Levy U (2003). Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27, 1113-1123.
48. Hof PR, Haroutunian V, Copland C, et al. (2002) Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res 27, 1193-1200.
49. Hof PR, Haroutunian V, Friedrich VL Jr., et al (2003). Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 53, 1075-1085.
50. Honey GD, Honey RA, O'Loughlin C, Sharar SR, Kumaran D, Suckling J, et al. (2005). Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15, 6, 749-759.
51. Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9, 984-997.
52. Javitt DC (2008). Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 63, 6-8.
53. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsycho-pharmacology 20, 201-225.
54. Jentsch JD, Redmond DE, Jr., Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277, 953-955.
55. Jessen F, Scheef L, Germeshausen L, Tawo Y, Kockler M, Kuhn KU, et al. (2003). Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. Am J Psychiatry 160, 7, 1305-1312.
56. Karoutzou G, Emrich HM, Dietrich DE (2008). The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 13, 3, 245-60.
57. Kauer JA, Malenka RC, Nicoll RA (1988). NMDA application potentiates synaptic transmission in the hippocampus. Nature 334, 6179, 250-252.
58. Keshavan MS (1999). Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 33, 6, 513-521.
59. Keshavan MS, Dick E, Mankowski I, Harenski K, Montrose DM, Diwadkar V, et al. (2002). Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia. Schizophr Res 58, 2-3, 173-183.
60. Kerwin R, Patel S, Meldrum B (1990). Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39, 1, 25-32.
61. Konorski J (1948). Conditioned reflexes and neuron organization. Cambridge University Press, Cambridge, U.K.
62. Konradi C, Heckers S (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97, 2, 153-79.
63. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Jr., Charney DS (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51, 199-214.
64. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007). NMDA receptors and schizophrenia. Curr Opin Pharmacol 7, 48-55.
65. Kubicki M, McCarley R, Westin CF, et al (2007). A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 41, 1-2, 15-30.
66. Law AJ, Deakin JF (2001). Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12, 13, 2971-4.
67. Law JR, Flanery MA, Wirth S, Yanike M, Smith AC, Frank LM, et al. (2005). Functional magnetic resonance imaging activity during the gradual acquisition and expression of paired-associate memory. J Neurosci 25, 24, 5720-5729.
68. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR (2006). Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. PNAS 103, 6747-6752.
69. Leube DT, Rapp A, Buchkremer G, Bartels M, Kircher TT, Erb M, et al. (2003). Hippocampal dysfunction during episodic memory encoding in patients with schizophrenia-an fMRI study. Schizophr Res 64, 1, 83-85.
70. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU (1999). Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46, 5, 616-626.
71. Lewis DA, Gonzalez-Burgos G (2006). Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12, 1016-1022.
72. Lewis DA, Moghaddam B (2006). Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 63, 10, 1372-1376.
73. MacDonald AW 3rd, Chafee MV (2006). Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18, 3, 853-876.
74. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 3, 141-150.
75. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Horoutunian V, Davis KL, Meador-Woodruff JH (2007). Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophrenia Res 90, 15-27.
76. McInnes LA, Lauriat TL (2006). RNA metabolism and dysmyelination in schizophrenia. Neurosci Biobehavioral Rev 30, 551-561.
77. Meador-Woodruff JH, Healy DJ (2000). Glutamate receptor expression in schizophrenic brain. Brain Res Rev 31, 2-3, 288-294.
78. Moghaddam B (2003). Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884.
79. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
80. Nakazawa K, Quirk MC, Chitwood RA, Watanabe M, Yeckel MF, Sun LD, et al. (2002). Requirement for hippocampal CA3 NMDA receptors in associative memory recall. Science 297, 5579, 211-218.
81. Nasrallah HA, Skinner TE, Schmalbrock P, Robitaille PM (1994). Proton magnetic resonance spectroscopy (1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatry 165, 4, 481-485.
82. Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, Williams HJ, Preece AC, Dwyer S, Wilkinson JC, Spurlock G, Kirov G, Buckland P, Waddington JL, Gill M, Corvin AP, Owen MJ, O'Donovan MC (2006). Evidence that interaction between Neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 141b, 96-101.
83. Nudmamud-Thanoi S, Piyabhan P, Harte MK, Cahir M, Reynolds GP (2007). Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J Neural Transm, Suppl 72, 281-5.
84. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, et al. (2007). Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study. J Psychiatr Res 41, 8, 625-34.
85. Olbrich HM, Valerius G, Rüsch N, Büchert M, Thiel T, Hennig J, Ebert D, Van Elst LT (2007). Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 5, 1-5.
86. O'Tuathaigh CM, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL (2007). Susceptibility genes for schizophrenia: characterisation of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 31, 60-78.
87. Paoletti P, Neyton J (2007). NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7, 1, 39-47.
88. Pellerin L, Magistretti PJ (1994). Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. PNAS 91, 10625-9.
89. Porter RH, Eastwood SL, Harrison PJ (1997). Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 751, 2, 217-31.
90. Pouwels PJ, Frahm J (1998). Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magnetic Resonance Medicine 39, 53-60.
91. Purdon SE, Valiakalayil A, Hanstock CC, Seres P, Tibbo P (2008). Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res 99, 1-3, 218-24.
92. Ranganath C, Heller A, Cohen MX, Brozinsky CJ, Rissman J (2005). Functional connectivity with the hippocampus during successful memory formation. Hippocampus 15, 8, 997-1005.
93. Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA (2005). Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuro-psychopharmacology 30, 3, 633-639.
94. Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, Benoit-Marand M, Chen C, Moore H, O'Donnell P, Brunner D, Corfas G (2007). Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. PNAS 104, 8131-8136.
95. Rubin Y, LaPlaca MC, Smith DH, Thibault LE, Lenkinski RE (1995). The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett 198, 3, 209-12.
96. Scarr E, Beneyto M, Meador-Woodruff JH, Deans B (2005). Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 30, 8, 1521-31.
97. Sekiguchi M, Wada K, Wenthold RJ (2007). N-acetylaspartylglutamate acts as an agonist upon homomeric NMDA receptor (NMDAR1) expressed in Xenopus oocytes. FEBS Lett 311, 285-289.
98. Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF, Petroff OA, Shulman GI, Shulman RG, Rothman DL (1999). Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. PNAS 96, 8235-40.
99. Simmons ML, Frondoza CG, Coyle JT (1991). Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 37-45.
100. Singer W (1994). Coherence as an organizing principle of cortical functions. Int Rev Neurobiol 37, 153-183.
101. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT (1996). An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophrenia Bulletin 22, 597-609.
102. Stanley JA, Pettegrew JW, Keshavan MS (2000). Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings-part I. Biological Psychiatry 48, 357-68.
103. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71, 877-892.
104. Stephan KE, Baldeweg T, Friston KJ (2006). Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 59, 10, 929-39.
105. Stone JM, Morrison PD, Pilowsky LS (2007). Glutamate and dopamine dysregulation in schizophrenia - a synthesis and selective review. J Psychopharmacol 21, 440-452.
106. Straub RE, Lipska BK, Egan MF, Goldberg TE, Callicott JH, Mayhew MB, Vakkalanka RK, Kolachana BS, Kleinman JE, Weinberger DR (2007). Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 12, 9, 854-69.
107. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. (1999). Genetic enhancement of learning and memory in mice. Nature 401, 6748, 63-69.
108. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA (2001). Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50, 117-122.
109. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159, 11, 1944-6.
110. Tkachev D, Mimmack ML, Ryan MM, et al (2003). Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362, 798-805.
111. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004). 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 161, 6, 1116-8.
112. Trombley PQ, Westbrook GL (1990). Excitatory synaptic transmission in cultures of rat olfactory bulb. J Neurophysiol 64, 2, 598-606.
113. Tsai G, Coyle JT (1995). N-Acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology 46, 531-540.
114. Tsai G, Coyle JT (2002). Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42, 165-179.
115. Tsai SJ (2005). Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med Sci Monit 11, 9, 39-45.
116. Tuominen HJ, Tiihonen J, Wahlbeck K (2006). Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev CD003730.
117. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V (2001). Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55, 597-610.
118. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI (2004). Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophrenia Res 67, 269-275.
119. Urenjak J, Williams SR, Gadian DG, Noble M (1993). Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neurosciences 13, 981-989.
120. Velakoulis D, Stuart GW, Wood SJ, Smith DJ, Brewer WJ, Desmond P, et al. (2001). Selective bilateral hippocampal volume loss in chronic schizophrenia. Biol Psychiatry 50, 7, 531-539.
121. Wirth S, Yanike M, Frank LM, Smith AC, Brown EN, Suzuki WA (2003). Single neurons in the monkey hippocampus and learning of new associations. Science 300, 5625, 1578-1581.